Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway

Acta Pharmacologica Sinica

Volumn 35, Issue 6, 2014, Pages 727-737

  Pang, Tao ^a   Sun, Li Xin ^a   Wang, Tao ^a   Jiang, Zhen Zhou ^a   Liao, Hong ^a   Zhang, Lu Yong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Akt; angiotensin II receptor blocker; apoptosis; Cerebellar granule cell; GSK 3 ; neurotoxicity; nutrient deprivation; PPAR ; telmisartan

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANGIOTENSIN 1A RECEPTOR; CANDESARTAN; CASPASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; LACTATE DEHYDROGENASE; LOSARTAN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN BCL 2; PROTEIN KINASE B; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NEUROPROTECTIVE AGENT;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION ASSAY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GRANULE CELL; IN VITRO STUDY; MALE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NICK END LABELING; NONHUMAN; NUTRIENT LIMITATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WST-1 ASSAY; ANIMAL; CELL CULTURE; CEREBELLUM; CYTOLOGY; DRUG EFFECTS; METABOLISM; NERVE CELL; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; BENZIMIDAZOLES; BENZOATES; CELLS, CULTURED; CEREBELLUM; FEMALE; GLYCOGEN SYNTHASE KINASE 3; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84902255843     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.199     Document Type: Article

References (66)

1. Dzau VJ, Ingelfinger J, Pratt RE, Ellison KE. Identification of renin and angiotensinogen messenger RNA sequences in mouse and rat brains. Hypertension 1986; 8: 544-8.
2. Gyurko R, Wielbo D, Phillips MI. Antisense inhibition of AT1 receptor mRNA and angi otensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept 1993; 49: 167-74.
3. Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H , et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke 2008; 40: 597-603.
4. Wright JW,Yamamoto BJ,Harding JW. Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets, Prog Neurobiol,2008, 84, 157-81.
5. AbdAlla S, Lother H, el Missiry A, Langer A, Sergeev P, el Faramawy, et al. Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J Biol Chem 2009; 284: 6554-65.
6. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer's diseasefriend or foe? Trends Neurosci 2009; 32: 619-28.
7. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 2009; 109: 656-69.
8. Schrader J, Lü ders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. Acute candesartan cilexetil therapy in Stroke Survivors Study group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in st roke survivors. Stroke 2003; 34: 1699-703.
9. Schrader J, Lü ders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. MOSES Study Group. Morbidity and mortality after stroke, Eprosartan comp ared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-26.
10. Krikov M, Thone-Reineke C, Müller S, Villringer A, Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens 2008; 26: 544-52.
11. Neldam S. Choosing an angiotensin- receptor blocker: blood pressure lowering, cardiovascular protection or both? Future Cardiol 2010; 6: 129-35.
12. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
13. Rotman N, Wahli W. PPAR modulation of kinase-linked receptor signaling in physiology and disease. Physiology (Bethesda) 2010; 25: 176-85.
14. Chen YC, Wu JS, Tsai HD, Huang CY, Chen JJ, Sun GY, et al. Peroxisome proli ferator-activated receptor gamma (PPAR-) and neurodegenerative disorders. Mol Neurobiol 2012; 46: 114-24.
15. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 1993; 262: 695-700.
16. Park DS, Levine B, Ferrari G, Greene LA. Cyclin dependent kinase inhibitors and domina nt negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci 1997; 17: 8975-83.
17. Hetman M, Kanning K, Cavanaugh JE, Xia Z. Neuroprotection by bra in-derived neurotrophic factor is mediated by extracellular signalregulated kinase and phosphatidylinositol 3-kinase. J Biol Chem 1999; 274: 22569-80.
18. Moule SK, Welsh GI, Edgell NJ, Foulstone EJ, Proud CG, Denton RM. Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by wortmannin-sensitive and-insensitive mechanisms. J B iol Chem 1997; 272: 7713-9.
19. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1998; 273: 19929-32.
20. Kawasaki H, Morooka T, Shimohama S, Kimura J, Hirano T, Gotoh Y, et al. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J Biol Chem 1997; 272: 18518-21.
21. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/ threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Na tl Acad Sci (USA) 1999; 96: 8745-50.
22. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase i nhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008; 28: 2576-88.
23. Villapol S, Yaszemski AK, Logan TT, Sánchez-Lemus E, Saavedra JM, Symes AJ. Candesar tan, an angiotensin II AT(1)-receptor blocker and PPAR- agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology 2012; 37: 2817-29.
24. Kasahara Y, Taguchi A, Uno H, Nakano A, Nakagomi T, Hirose H. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res 2010; 1340: 70-80.
25. Tsukud a K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, et al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor- gamma activation. Hypertension 2009; 54: 782-7.
26. Hetman M,Cavanaugh JE,Kimelman D,Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal, J Neurosci,2000 ,20,2567-74.
27. Benicky J, Sá nchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011; 36: 857-70.
28. Jantas D, Lorenc-Koci E, Kubera M, Lason W. Neuroprotective effects of MAPK/ERK1/2 and calpain inhibitors on lactacystin-induced cell damage in primary cortical neurons. Neurotoxicology 2011; 32: 845-56.
29. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 2000; 407: 802-9.
30. Lee SM, Wong MD, Samii A, Ho vda DA. Evidence for energy failure following irreversible traumatic brain injury. Ann N Y Acad Sci 1999; 893: 337-40.
31. Chiong M, Wang ZV, Pedrozo Z, Cao DJ, Troncoso R, Ibacache M, et al. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis 2011; 2: e244.
32. Seneff S, Wainwright G, Mascitelli L. Nutrition and Alzheimer's disease: the detrimental role of a high carbohydrate diet. Eur J Intern Med 2011; 22: 134-40.
33. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149-67.
34. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
35. Jing G, Grammatopoulos T, Ferguson P, Schelman W, Weyhenmeyer J. Inhibitory effects of angiotensin on NMDA-induced cytotoxicity in primary neuronal cultures. Brain Res Bull 2004; 62: 397-403.
36. Schel man WR, Andres R, Ferguson P, Orr B, Kang E, Weyhenmeyer JA. Angiotensin II attenuates NMDA receptor-mediated neuronal cell death and prevents the associated reduction in Bcl-2 expression. Brain Res Mol Brain Res 2004; 128: 20-9.
37. Pang T, Wang J, Benicky J, Sánchez-Lemus E, Saavedra JM. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1 partly through the JNK/c-Jun and NADPH oxidase pathways . J Neuroinflammation 2012; 9: 102.
38. Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, et al. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, corti cal tissue loss, and inflammation following traumatic brain injury. Exp Neurol 2011; 227: 128-35.
39. Min LJ, Mogi M, Shudou M, Jing F, Tsukuda K, Ohshima K, et al. Peroxisome prolife rator-activated receptor-gamma activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 2012; 59: 1079-88.
40. Zorad S, Dou J, Benicky J, Hutanu D, Tybitanclova K, Zhou J, et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin an d PPAR. Eur J Pharm 2006; 552: 112-22.
41. Koh EJ, Yoon SJ, Lee SM. Losartan protects liver against ischemiareperfusion injury through PPAR activation and receptor for advanced glycation end-product s down-regulation. Br J Pharmacol 2013; 169: 1404-16.
42. An J, Nakajima T, Kuba K, Kimura A. Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages. Hypertens Res 2010; 33: 831-5.
43. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, et al. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagoni sts. Vascul Pharmacol 2006; 45: 154-62.
44. Pang T, Benicky J, Wang J, Orecna M, Sanchez-Lemus E, Saavedra JM. Telmisartan ameliorates lipopolysaccharide-induced innate immune response thr ough peroxisome proliferator-activated receptor- activation in human monocytes. J Hypertens 2012; 30: 87-96.
45. Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A, Jing F, et al. Low do se of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. J Hypertens 2010; 28: 1730-7.
46. Garrido-Gil P, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Involvement of PPAR- in the neuroprotective and antiinflammatory effects of angiotensin type receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease, J Neuroinflammation , 2012, 9,38.
47. Zhao X, Ou Z, Grotta JC, Waxham N, Aronowski J. Peroxisomeproliferator- activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res 2006; 1073 -1074: 460-9.
48. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpres sion after focal cerebral ischemia in rats. FASEB J 2006; 20: 1162-75.
49. Zuhayra M, Zhao Y, von Forstner C, Henze E, Gohlke P, Culman J, et al. Activation of cerebral peroxisome prol iferator-activated receptors (PPAR) reduces neuronal damage in the substantia nigra after transient focal cerebral ischaemia in the rat. Neuropathol Appl Neurobiol 2011; 37: 738-52.
50. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005; 191: 331-6.
51. Kiaei M. Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res 2008; 2008: 418765.
52. Finkbeiner S. CREB couples neurotrophin signals to survival messages. Neuron 2000; 25: 11-4.
53. Zhu D, Jiang X, Wu X, Tian F, Mearow K, Lipsky RH, et al. Inhibition of protein kinase C promotes neuronal survival in low potassium thr ough an Akt-dependent pathway. Neurotox Res 2004; 6: 281-9.
54. Vaillant AR, Mazzoni I, Tudan C, Boudreau M, Kaplan DR, Miller FD. Depolarization and neurotrophins converge on the phosphat idylinositol 3-kinase-Akt pathway to synergistically regulate neuronal survival. J Cell Biol 1999; 146: 955-66.
55. Kumari S, Liu X, Nguyen T, Zhang X, D'Mello SR. Distinct phosphorylation pat terns underlie Akt activation by different survival factors in neurons. Brain Res Mol Brain Res 2001; 96: 157-62.
56. Wang LX, Sun Y, Chen C, Huang XY, Lin Q, Qian GQ, et al. Effects a nd mechanism of oridonin on pulmonary hypertension induced by chronic hypoxia-hypercapnia in rats. Chin Med J (Engl) 2009; 122: 1380-7.
57. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-911.
58. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, et al. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 2007; 282: 37006-15.
59. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
60. Bha t RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci USA 2000; 97: 11074-9.
61. Jin N, Ková cs AD, Sui Z, Dewhurst S, Maggirwar SB. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 2005; 48: 576-83.
62. Chuang DM, Wang Z, Chiu CT. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2 011; 4: 15.
63. Liang MH, Chuang DM. Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem 2007; 282: 3904-17.
64. Liu F, G ong X, Zhang G, Marquis K, Reinhart P, Andree TH. The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. J Neurochem 2005; 95: 1363-72.
65. Kelly S, Zhao H, Hua Sun G, Cheng D, Qiao Y, Luo J, et al. Glycogen synthase kinase 3beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate ex citotoxicity, and cerebral ischemia. Exp Neurol 2004; 188: 378-86.
66. Endo H, Nito C, Kamada H, Nishi T, Chan PH. Activation of the Akt/GSK3beta signaling pathway mediates survival of vulnera ble hippocampal neurons after transient global cerebral ischemia in rats. J Cereb Blood Flow Metab 2006; 26: 1479-89.